[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616990":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":35,"locations":41,"responsibleParty":57,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":26,"overallStatus":79,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","Period 1 : Treatment A(AD-2321), Period 2 : Treatment C(AD-2321+AD-2322)",[13,14],"Drug: Treatment A(AD-2321)","Drug: Treatment C(AD-2321+AD-2322)",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm B","Period 1 : Treatment B(AD-2322), Period 2 : Treatment C(AD-2321+AD-2322)",[19,14],"Drug: Treatment B(AD-2322)",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Treatment A(AD-2321)","AD-2321 Oral Tablet",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Treatment B(AD-2322)","AD-2322 Oral Tablet",[16],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Treatment C(AD-2321+AD-2322)","AD-2321 Oral Tablet+AD-2322 Oral Tablet",[9,16],[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"SoonKeun Kwon","CONTACT","+82318916915","skkwon@addpharma.co.kr",[42],{"facility":43,"status":26,"city":44,"state":26,"zip":26,"country":45,"countryCode":26,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"H+ Yangji Hospital","Seoul","South Korea",{"type":47,"coordinates":48},"Point",[49,50],126.9784,37.566,{"lat":50,"lon":49},[53],{"name":54,"role":38,"phone":55,"phoneExt":26,"email":56},"SeungHyun Kang","+82-70-4665-9490","juspa@newyjh.com",{"type":58,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100616990","phase-1-evaluate-the-pharmacokinetic-interaction-and-the-safety-of-ad-2321-and-ad-2322-100616990",false,"NCT07312799","Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322","A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥19 and \\\u003C65 years at the time of the screening visit\n* Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at the time of the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":71,"type":72},41,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.",[78],"Hypertension","NOT_YET_RECRUITING","2025-12-17",{"date":82,"type":83},"2025-12-31","ACTUAL",{"date":85,"type":72},"2026-01-27",{"date":87,"type":72},"2026-02-26",{"name":5,"class":6},1]